Cargando…
BASIC: A Bayesian adaptive synthetic-control design for phase II clinical trials
BACKGROUND: Randomized controlled trials are considered the gold standard for evaluating experimental treatments but often require large sample sizes. Single-arm trials require smaller sample sizes but are subject to bias when using historical control data for comparative inferences. This article pr...
Autores principales: | Jiang, Liyun, Thall, Peter F, Yan, Fangrong, Kopetz, Scott, Yuan, Ying |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10504821/ https://www.ncbi.nlm.nih.gov/pubmed/37313712 http://dx.doi.org/10.1177/17407745231176445 |
Ejemplares similares
-
IBIS: identify biomarker-based subgroups with a Bayesian enrichment design for targeted combination therapy
por: Chen, Xin, et al.
Publicado: (2023) -
Adaptive designs for phase II cross-over dose-finding trials using Bayesian model averaging
por: Simpson, Sarah, et al.
Publicado: (2015) -
The Bayesian Design of Adaptive Clinical Trials
por: Giovagnoli, Alessandra
Publicado: (2021) -
A Bayesian pick-the-winner design in a randomized phase II clinical trial
por: Chen, Dung-Tsa, et al.
Publicado: (2017) -
Phase II Trials in Drug Development and Adaptive Trial Design
por: Van Norman, Gail A.
Publicado: (2019)